Entacapone Augmentation for Schizophrenia

Rambam Health Care Campus

Status: Completed

Conditions: Schizophrenia

Treatments: Drug: Entacapone

Study type: Interventional

Funder types: Other

Identifiers

NCT00192855

entacapon.schiz.CTIL

Details and patient eligibility

About

This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.

Enrollment: 52 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• predominantly negative symptoms
• stable on ongoing antipsychotic treatment

Exclusion criteria

• acute psychotic exacerbation
• suicidal ideation
• uncontrolled systemic disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Double Blind